Nathan Zelyas

Nathan Zelyas

Auto-generated profile, based on publicly available information

Nathan Zelyas

Department of Laboratory Medicine and Pathology, University of Alberta; Edmonton, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
ADAlexander Doroshenko
Alexander Doroshenko
NLNelson Lee
Nelson Lee
CMClayton MacDonald
Clayton MacDonald
NZNathan Zelyas
Nathan Zelyas
LALeyla Asadi
Leyla Asadi
JKJamil N. Kanji
Jamil N. Kanji
To determine the incidence of influenza and noninfluenza respiratory viruses (NIRVs) pre-/post-implementation of public health measures aimed to decrease coronavirus disease 2019 (COVID-19) transmission using population-based surveillance data. We hypothesized that such measures could reduce the burden of respiratory viruses (RVs) transmitting via the same routes. An interrupted time-series analysis of RV surveillance data in Alberta, Canada, from May 2017 to July 2020 was conducted. The burden of influenza and NIRVs before and after intervention initiation at week 11 was compared. The analysis was adjusted for seasonality, overdispersion, and autocorrelation. During the study period, an average of 708 and 4056 weekly respiratory multiplex molecular panels were conducted pre-/post-intervention, respectively. We found significant reductions in test positivity rates in the postintervention period for influenza (-94.3%; 95% CI, -93.8 to 97.4%; P<.001) and all NIRVs (-76.5%; 95% CI, -77.3 to -75.8%; P<.001) in the crude model, and -86.2% (95% CI, -91.5 to -77.4%: P<.001) and -75% (95% CI, -79.7 to -69.3%; P<.001), respectively, in the adjusted models. Subanalyses for individual viruses showed significant decreases in respiratory syncytial virus, human metapneumovirus, enterovirus/rhinovirus, and parainfluenza. For non–severe acute respiratory coronavirus 2 human coronaviruses, the decline was not statistically significant after adjustment (-22.3%; 95% CI, -49.3 to +19%, P=.246). The implementation of COVID-19 public health measures likely resulted in reduced transmission of common RVs. Although drastic lockdowns are unlikely to be required given widespread COVID-19 vaccination, targeted implementation of such measures can lower RV disease burden. Studies to evaluate relative contributions of individual interventions are warranted.

3 September 2021 in Microbiology Spectrum
Verified
Journal Article
Open access
NZNathan Zelyas
Nathan Zelyas
KPKanti Pabbaraju
Kanti Pabbaraju
MCMatthew A Croxen
Matthew A Croxen
TLTarah Lynch
Tarah Lynch
EBEmily Buss
Emily Buss
GTGraham Tipples
Graham Tipples
Different strains, or variants, of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19) have emerged that have higher levels of transmission, less susceptibility to our immune response, and possibly cause more severe disease than previous strains of the virus. Rapid detection of these variants of concern is important to help contain them and prevent them from spreading widely within the population.

1 July 2021 in Journal of Virological Methods
Verified
Journal Article
Closed access
KPKanti Pabbaraju
Kanti Pabbaraju
AWAnita A. Wong
Anita A. Wong
RMRaymond Ma
Raymond Ma
NZNathan Zelyas
Nathan Zelyas
GTGraham A. Tipples
Graham A. Tipples

3 September 2021 in Microbiology Spectrum
Verified
Journal Article
Open access
CCCarmen Lynn Charlton
Carmen Lynn Charlton
LNLeonard T Nguyen
Leonard T Nguyen
ABAshley Bailey
Ashley Bailey
JFJayne Fenton
Jayne Fenton
SPSabrina S Plitt
Sabrina S Plitt
GTGraham Tipples
Graham Tipples
Using SARS-CoV-2 serology testing, we assessed the proportion of people in Alberta, Canada (population 4.4 million) positive for COVID-19 antibodies, indicating previous infection, during the first two waves of the COVID-19 pandemic (prior to vaccination programs). Linking these results with sociodemographic population data provides valuable information as to which groups of the population are more likely to have been infected with the SARS-CoV-2 virus to help facilitate public health decision-making and interventions.

11 November 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
BBBruno Fernando Buzo
Bruno Fernando Buzo
JPJutta K. Preiksaitis
Jutta K. Preiksaitis
KHKieran Halloran
Kieran Halloran
JNJayan Nagendran
Jayan Nagendran
DTDerek R. Townsend
Derek R. Townsend
WSWendy I. Sligl
Wendy I. Sligl
Hyperammonemia syndrome (HS) is a rare complication with high mortality described after lung transplantation. Its pathophysiology is still unclear, but previous studies, including murine models, have linked the identification of Mycoplasmataceae in airway specimens with HS occurrence. This study explores the association between Mycoplasmataceae polymerase chain reaction (PCR) positivity, ammonia levels, HS and mortality post‐lung transplant. Adults who underwent lung transplantation between July 2017 and August 2019 had prospective surveillance testing for Mycoplasma and Ureaplasma using PCR on post‐operative bronchoscopy samples. 159 patients underwent lung transplantation during the study period. Mean age was 54 (±13) years; baseline diseases were predominantly pulmonary fibrosis (37.7%) and chronic obstructive pulmonary disease (35.8%). Mycoplasma and/or Ureaplasma airway positivity was found in 42 (26.4%) of tested patients, represented mostly by M. salivarium (26/43; 60.4%), U. parvum (7/43; 16.2%) and U. urealyticum (5/43; 11.6%). Median peak ammonia levels were higher in those with Ureaplasma colonization compared to uncolonized patients (p=0.04) however only three patients developed HS. Recipient airway Ureaplasma‐positivity was independently associated with younger (aOR 0.94, 95%CI 0.88‐0.99, p=0.04) and female donors (aOR 4.29; 95%CI 1.01‐18.2, p=0.05).

1 May 2021 in Virology Journal
Verified
Journal Article
Open access
PDF file
NMNatalie C. Marshall
Natalie C. Marshall
RKRuwandi M. Kariyawasam
Ruwandi M. Kariyawasam
NZNathan Zelyas
Nathan Zelyas
JKJamil N. Kanji
Jamil N. Kanji
MDMathew A. Diggle
Mathew A. Diggle
Background: SARS-CoV-2 infection can present with a broad clinical differential that includes many other respiratory viruses; therefore, accurate tests are crucial to distinguish true COVID-19 cases from pathogens that do not require urgent public health interventions. Co-circulation of other respiratory viruses is largely unknown during the COVID-19 pandemic but would inform strategies to rapidly and accurately test patients with respiratory symptoms. Methods: This study retrospectively examined 298,415 respiratory specimens collected from symptomatic patients for SARS-CoV-2 testing in the three months since COVID-19 was initially documented in the province of Alberta, Canada (March-May, 2020). By focusing on 52,285 specimens that were also tested with the Luminex Respiratory Pathogen Panel for 17 other pathogens, this study examines the prevalence of 18 potentially co-circulating pathogens and their relative rates in prior years versus since COVID-19 emerged, including four endemic coronaviruses. Results: SARS-CoV-2 was identified in 2.2% of all specimens. Parallel broad multiplex testing detected additional pathogens in only 3.4% of these SARS-CoV-2-positive specimens: significantly less than in SARS-CoV-2-negative specimens (p < 0.0001), suggesting very low rates of SARS-CoV-2 co-infection. Furthermore, the overall co-infection rate was significantly lower among specimens with SARS-CoV-2 detected (p < 0.0001). Finally, less than 0.005% of all specimens tested positive for both SARS-CoV-2 and any of the four endemic coronaviruses tested, strongly suggesting neither co-infection nor cross-reactivity between these coronaviruses. Conclusions: Broad respiratory pathogen testing rarely detected additional pathogens in SARS-CoV-2-positive specimens. While helpful to understand co-circulation of respiratory viruses causing similar symptoms as COVID-19, ultimately these broad tests were resource-intensive and inflexible in a time when clinical laboratories face unprecedented demand for respiratory virus testing, with further increases expected during influenza season. A transition from broad, multiplex tests toward streamlined diagnostic algorithms targeting respiratory pathogens of public health concern could simultaneously reduce the overall burden on clinical laboratories while prioritizing testing of pathogens of public health importance. This is particularly valuable with ongoing strains on testing resources, exacerbated during influenza seasons.